Arizona State Retirement System Has $236,000 Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Arizona State Retirement System boosted its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 4.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,993 shares of the company’s stock after buying an additional 258 shares during the period. Arizona State Retirement System’s holdings in Apogee Therapeutics were worth $236,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. EntryPoint Capital LLC boosted its position in shares of Apogee Therapeutics by 44.7% during the 1st quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock valued at $133,000 after acquiring an additional 617 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Apogee Therapeutics during the second quarter worth about $143,000. Kennedy Capital Management LLC acquired a new stake in Apogee Therapeutics during the first quarter valued at approximately $212,000. Principal Financial Group Inc. grew its stake in shares of Apogee Therapeutics by 26.3% in the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock valued at $253,000 after purchasing an additional 1,340 shares during the period. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Apogee Therapeutics by 111.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock valued at $274,000 after purchasing an additional 2,172 shares during the period. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Price Performance

Apogee Therapeutics stock opened at $50.64 on Wednesday. The business has a 50 day simple moving average of $47.21 and a 200 day simple moving average of $49.82. The company has a market capitalization of $2.28 billion, a PE ratio of -9.60 and a beta of 2.74. Apogee Therapeutics, Inc. has a one year low of $14.19 and a one year high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.60). Equities analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Insider Activity at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,995 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total transaction of $225,412.00. Following the sale, the insider now directly owns 294,793 shares of the company’s stock, valued at $11,084,216.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Apogee Therapeutics news, insider Carl Dambkowski sold 5,995 shares of Apogee Therapeutics stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total value of $225,412.00. Following the completion of the transaction, the insider now owns 294,793 shares in the company, valued at approximately $11,084,216.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction on Friday, July 5th. The stock was sold at an average price of $37.26, for a total value of $558,900.00. Following the sale, the chief executive officer now owns 1,474,487 shares in the company, valued at approximately $54,939,385.62. The disclosure for this sale can be found here. Insiders sold 120,995 shares of company stock valued at $5,218,774 in the last ninety days. Insiders own 36.10% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.